Types of Breast Cancer

DCIS stands for Ductal Carcinoma In Situ - a Latin phrase meaning "in place." It is the earliest form of breast cancer, in which abnormal cells have developed inside one of the breast's milk ducts but have not broken through the duct wall into the surrounding breast tissue. Because the cells haven't invaded, DCIS cannot spread to lymph nodes or other organs at this stage.

DCIS is sometimes called a "pre-cancer" or Stage 0 breast cancer. While it is not yet life-threatening, it is important to treat it because, if left alone, some cases of DCIS can eventually progress into invasive breast cancer. The challenge is that doctors cannot always predict which DCIS cases will progress and which won't - which is why treatment is generally recommended.

Invasive ductal carcinoma (IDC) - also called infiltrating ductal carcinoma - starts in the cells lining a breast milk duct and then breaks through the duct wall into the surrounding breast tissue. From there, it has the potential to spread to nearby lymph nodes and, if untreated, to distant organs via the lymphatic system or bloodstream.

IDC is the most common form of breast cancer in both women and men. The word "invasive" describes that the cells have left their original location - it does not mean the cancer has necessarily spread beyond the breast. Many IDC cases are caught at an early stage when they are very treatable. Treatment and prognosis depend on the tumor size, grade, hormone receptor status, HER2 status, and lymph node involvement.

Invasive lobular carcinoma (ILC) begins in the lobules - the milk-producing glands at the end of the breast ducts - and then grows into the surrounding breast tissue. ILC is the second most common type of invasive breast cancer. What makes ILC unique is how it grows: ILC cells typically lack a protein called E-cadherin that normally keeps cells together. Without it, ILC cells spread in single-file lines through fatty breast tissue rather than forming a compact mass.

This diffuse, sheet-like growth pattern makes ILC uniquely challenging: it can be difficult to see on a standard mammogram and may not form a palpable lump. Instead, you might notice a vague area of thickening or fullness. Because of this, ILC is often larger at the time of diagnosis than IDC. Breast MRI or contrast-enhanced mammography (CEM) are significantly more accurate at detecting the full extent of ILC.

Triple-negative breast cancer (TNBC) gets its name from a laboratory test result: the cancer cells test negative for estrogen receptors (ER−), progesterone receptors (PR−), and HER2 (HER2−). These three receptors are the most common "drivers" that fuel breast cancer growth. Because TNBC lacks all three, it cannot be treated with hormone therapy (like tamoxifen) or HER2-targeted therapy (like trastuzumab).

TNBC tends to be more aggressive - it grows faster, is more likely to spread before diagnosis, and is more likely to recur than hormone-positive cancers. However, there is an important upside: TNBC often responds exceptionally well to chemotherapy. When treated with chemotherapy before surgery, many patients achieve a complete pathological response (no cancer remaining in the tissue) - a strong predictor of long-term cure. Newer treatments including immunotherapy and PARP inhibitors are also improving outcomes significantly.

HER2 stands for Human Epidermal growth factor Receptor 2 - a protein found on the surface of all breast cells that helps control how cells grow and divide. In HER2-positive breast cancer, the cancer cells have too many copies of the HER2 gene (called amplification), which causes them to produce an excess of HER2 receptors. This flood of receptors sends constant "grow and divide" signals to the cell, making the cancer more aggressive and faster-growing.

For decades, HER2-positive breast cancer was considered one of the worst prognoses. That changed dramatically in the 1990s and 2000s with the development of targeted therapies specifically designed to block the HER2 receptor. Trastuzumab (Herceptin) - the first HER2-targeted drug - combined with chemotherapy reduces the risk of recurrence by 50% and improves overall survival by 30%. Today, survival rates for early-stage HER2-positive breast cancer exceed 90%, matching outcomes for hormone-positive disease.

Inflammatory breast cancer (IBC) is a rare but aggressive form of breast cancer in which cancer cells block the lymph vessels in the skin of the breast. This blockage causes the breast to look red, swollen, and warm - symptoms that often resemble a breast infection (mastitis). Unlike most breast cancers, IBC usually does not form a lump. The breast may feel heavier and look different, with skin that appears dimpled or pitted like the skin of an orange (called peau d'orange).

IBC progresses rapidly - sometimes developing from subtle symptoms to a clearly affected breast over just weeks. Because it resembles infection, it is sometimes misdiagnosed as mastitis and treated with antibiotics before the correct diagnosis is made. If breast redness and swelling do not improve with antibiotics within a week or two, a biopsy should be performed urgently. At diagnosis, IBC is always classified as at least Stage III, and if it has spread to distant organs, Stage IV.

While IDC and ILC together account for the vast majority of breast cancers, a number of other, rarer types exist. Each has its own unique appearance under the microscope and its own clinical behavior. Your pathology report may name one of these types. Here is an overview of the most important ones: